



Weekly Research Reports

Disclosures and Disclaimer : This report must be read with the disclosures in the Disclosure appendix, and with the Disclaimer, which forms part of it. This document does not contain any investment views or opinions. The Registration Number of the Research Analyst is : INH100005011

www.shareindia.com



CONTENTS

Title	Page No.
Share India (Wealth Weekly)	03-04
Top Sectors for the Week	05-15
Weekly Pivot Table (Equities)	16
Weekly Pivot Table (Commodities)	17
Disclaimer	18



WEALTH WEEKLY



Share India Wealth Weekly... Getting rich is easy with help of Share India Wealth Weekly.

This weekly research report helps you to identify the best five momentum stocks for the week. 'Pick of the week' is best among the mentioned five and is always with detailed 'Technical & Macro outlook'.

The trick to "Get Rich quickly and to Stay Rich forever" is a combination of alertness and awareness. With the right information on stocks from Excel Stock Wealth Weekly, your money is likely to grow confidently and living the "rich" life, is achievable.

You generate, we multiply

www.shareindia.com

STOCKS	CMP	BIAS	TRADING / INVESTMENT STRATEGY
AUROBINDO PHARMA	1242	Positive	Aurobindo Pharma Ltd. was incorporated in the year 1986 and now commands a market cap of Rs. 72,756 Crores. Founded by Mr. P. V. Ramprasad Reddy and Mr. K. Nityananda Reddy, the firm develops, manufactures, and commercialises a diverse portfolio of generics, specialty products and injectables, active pharmaceutical ingredients and complex offerings including biosimilars, vaccines, peptides, and metered dose inhalers globally in over 150 countries. The firm has 29 manufacturing and packaging facilities that are approved by leading regulatory agencies including the US FDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The robust product portfolio is spread over 7 major therapeutic and product areas encompassing CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up. Simply buy at CMP, and on dips between 1100-1150 zone, targeting 1351/1477 mark and then at psychological 1600 mark. Holding Period: 15 Months+
ITC	465	Positive	ITC is one of India's foremost private sector companies and a diversified conglomerate with businesses spanning Fast Moving Consumer Goods, Hotels, Paperboards and Packaging, Agri Business and Information Technology. Over the last decade, ITC's new Consumer Goods Businesses have established a vibrant portfolio of 25+ world-class Indian brands that create and retain value in India. ITC's world class FMCG brands including Aashirvaad, Sunfeast, Yippee!, Bingo!, B Natural, ITC Master Chef, Fabelle, Sunbean, Fiamsa, Engage, Vivel, Savlon, Classmate, Paperkraft, Mangaldeep, Aim and others have garnered encouraging consumer franchise within a short span of time. While several of these brands are market leaders in their segments, others are making appreciable progress. ITC reported a healthy set of Q2FY25 results (September quarter). The company's consolidated profit for the period came in at Rs 5,054.4 crore, up 1.8% year-on-year (Y-o-Y), from Rs 4,964.5 crore in the same quarter a year ago (Q2FY24). Look to accumulate at CMP, and on dips between 410-420 zone, targeting 529 and then aggressive targets at 600 with stop below 373. Holding Period: 12 months.
M&M	2906	Positive	Incorporated in the year 1945, M&M is the flagship company of Mahindra Group and operates in the automotive and tractor segments and importantly, is virtually present across all segments like commercial vehicles, trucks, buses, vans, passenger cars, utility vehicles, and electric vehicles (EV), as well as motorcycles; aero and defense products; offers construction equipment, such as rotaries, tillers, loaders, and backhoes under the Mahindra EarthMaster brand; and road construction equipment comprising motor graders under the Mahindra RoadMaster brand. It is also involved in the provision of farm equipment, including tractors under the Mahindra, Swaraj, and Trakstar brands, as well as farm mechanization solutions, such as rotavators, cultivators, harvesters, rice transplanters, balers, sprayers, and implements and attachments; and renewable energy business comprising installation of EV chargers and provision of Li-ion batteries. Apart from the core business, M&M is also the promoter/holds a controlling interest in companies that are engaged in diverse businesses under the Mahindra brand (IT services, NBFC, logistics, hospitality, real estate, and auto ancillary business). Simply buy at CMP, and on dips between 2600-2650 zone, targeting 3125/3301 mark and then at 3551 mark. Stop below 2379. Holding Period: 9-12 Months.
SUN PHARMA	1809	Positive	Sun Pharma is among the largest players in the domestic formulations market and is the Fourth largest speciality generic pharmaceutical company in the world with global revenues of US\$ 5.4 billion and supported by 43 manufacturing facilities. It makes Specialty products, branded generics, complex generics, pure generics & APIs for chronic therapy areas such as cardiology, psychiatry, neurology, etc. The firm has capabilities across dosage forms like injectables, sprays, ointments, creams, liquids, tablets and capsules R&D and Manufacturing. Sun has forayed into regulated markets by acquiring majority stake in CaracoPharma and has strengthened its presence in US by recent acquisition of Taro. The positive catalyst in favor of the stock price is the improving traction in the specialty portfolio, India formulations and US specialty products business, industry-level growth in domestic formulation (DF) and increasing pace of approvals in the US generics segment. Technically, brace yourselves for an impulse uptrend on the weekly time scale with positive SAR series and most importantly, a "higher consolidation Pattern" on daily charts. The 200 days Exponential Moving Average (EMA) of the stock on the daily chart is currently at 1683 zone. A potential entrance exists at CMP, and on dips between 1600-1650 zone, targeting 1963 and then aggressive targets at psychological 2200 mark. Stop 1587. Holding period 9-12 months.
TEJAS NETWORKS	1217	Positive	Tejas Networks Ltd is India's largest R&D-driven telecom equipment company and designs, manufactures and sells leading-edge telecom products used by communication service providers, utilities, defence and government entities in over 75 countries. The company has a full range of products for building end-to-end networks including wireless (4G/5G), optical transmission (DWDM, OTN) and packet switching (Ethernet, IP/MPLS) that can be managed by a universal, multi-technology network management system. The company is a top-10 global supplier in the optical aggregation and broadband access segments, has filed 440+ patents and is ranked amongst Top-3 listed companies in India, in terms of percentage of revenues spent on R&D. Tejas Networks is a part of the Tata Group. Preferred Strategy: Look to accumulate at CMP, and on dips between 1000-1050 zone, targeting 1500/1751 and then aggressive targets at 2000 with stop below 877. Holding Period: 12-15 months.

Analyst's Pick: Buy AUROBINDO PHARMA (CMP 1242. Target: 1500)

Aurobindo Pharma Ltd. was incorporated in the year 1986 and now commands a market cap of Rs. 72,756 Crores. Founded by Mr. P. V. Ramprasad Reddy and Mr. K. Nityananda Reddy, the firm develops, manufactures, and commercialises a diverse portfolio of generics, specialty products and injectables, active pharmaceutical ingredients and complex offerings including biosimilars, vaccines, peptides, and metered dose inhalers globally in over 150 countries.

The positive catalysts:


- India's second largest pharmaceutical company in terms of revenue, is an integrated global pharmaceutical company headquartered in Hyderabad, India.
- The firm has 29 manufacturing and packaging facilities that are approved by leading regulatory agencies including the US FDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA.
- The robust product portfolio is spread over 7 major therapeutic and product areas encompassing CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.
- Aurobindo Pharma Limited consolidated financial results for the quarter ended September 30, 2024:
 - # Net Profit for the period stood at Rs. 817 crore, vs. Rs. 752 crore in Q2FY24.
 - # Revenue from Operations increased by 8% YoY to Rs 7,796 crore with growth across the businesses.
 - # EBITDA stood at Rs. 1,566 crores with a margin of 20.1% after absorbing higher the R&D costs. EBITDA before R&D was 25.1% and stood at Rs. 1,954 crores versus Rs. 1,936 crores in Q1 FY25.
 - # US formulations (excluding Puerto Rico) revenue increased by 4.3% to Rs. 3,530 crore.
 - # Europe formulations revenue increased by 19% to YoY to Rs. 2,105 crore.
 - # Growth markets revenue increased by 44 YoY to Rs. 812 crore.
 - # 37000+ employees
 - # Out of the total of 227 speciality and injectable ANDA filings as on 30th September 2024, of which 170 have final approval and remaining 57 are awaiting final approval. During the quarter, Aurobindo has filed 10 ANDAs, received final approval of 8 ANDAs and launched 14 products. The company as on 30th September, has 848 ANDAs filed with USFDA on a cumulative basis, out of which 676 have final approval and 26 have tentative approval, and 146 ANDAs are under review.

Outlook: The firm remains confident in maintaining growth momentum, supported by increased volumes, new product launches and stable pricing dynamics. The current pricing environment in the US market is likely to persist, providing a stable foundation for the performance. Europe and growth markets are anticipated to continue their positive growth. The firm is ramping up the capacities in Penicillin G, 6-APA, Granulation and China, which will drive further operational efficiencies and support our growth objectives in the coming quarter. The firm should be able to achieve break-even in the Penicillin G product facility by Q4 FY25 and start contributing positively from FY26 onwards.

Technically, brace yourselves for a major rebound play from a probable classic 'flag pattern' breakout on the yearly charts. An impulse uptrend is seen forming on the daily time scale, with positive SAR series, with recent sequence of higher high/low intact on the weekly and monthly charts.

Add to that a bullish divergence and a rising stochastic signal (on weekly charts) with recent increase in volumes signaling a larger rebound. The 200 days Exponential Moving Average (EMA) of the stock on the daily chart is currently at 1297-1305 zone. The level of Rs 1300 zone will act as a strong resistance zone.

Simply buy at CMP, and on dips between 1100-1150 zone, targeting 1351/1477 mark and then at psychological 1600 mark. Holding Period: 12 Months+



TOP SECTOR OF THE WEEK

Top Sectors for the Week is a Technical and Macro report containing everything you need to have...a clear, precise and detailed view on the five top momentum sectors... listed in BSE. This detailed multi-analyzed Macro-Technical report is a smart way to enter or exit an outperforming or underperforming sector using the relative strength function.

Top Sectors for the Week reports have an unbeatable track record...You can look out for our previous reports at our website www.shareindia.com



Sector Analysis: Relative Strength Performance

Sectors	Relative to Nifty...	Outperforming stocks	Underperforming stocks
Nifty Auto Index	UNDERPERFORM	M&M, EICHER MOTOR	BHARAT FORGE, HEROMOTO CORP
Bank Nifty Index	NEUTRAL	BANK OF BARODA, ICICI BANK	AU BANK, IDFC FIRST BANK, KOTAK BANK
Nifty IT Index	NEUTRAL	PERSISTENT SYSTEMS, HCL TECH, MPHASIS, OFSS	BSOFT, LTTS
Nifty Pharma Index	OUTPERFORM	SUN PHARMA, LUPIN	GRANNULES
Nifty Metals Index	UNDERPERFORM	RATNAMANI METALS	SAIL, NMDC, TATA STEEL

From Share India Research Desk...

The Week That Was

December 16th to December 20th 2024.

Nifty Bulls get Mauled by the Rampaging Bears.

The negative takeaway was that Dalal Street was under siege as the bears were everywhere, attacking Nifty and its stocks again and again.

Nifty (-4.77%, 23588)
Sensex (-4.98%, 78042)

Amidst turbulence and rocky environment, Nifty plunged in the week gone by and most importantly, did closed below its 200 DMA at 23834 mark.

All of that selling is tied to 7-big bad news from:

- 1) The trading theme revolved around Jerome Powell's hawkish outlook for 2025. (The Federal Reserve lowered its benchmark interest rate by 25 basis points to 4.25%-4.55%, marking the third consecutive reduction this year. The Fed delivered its expected quarter-point interest rate cut but trimmed projections for follow-on moves in 2025 to only two additional cuts, compared to a full percentage point in the last projection from September).
- 2) Intense FIIs selling (In the week gone by, FIIs have pulled out over Rs 15828 crore from Indian equities).
- 3) India's slowing economic growth, which is likely to mean that capital flows will be weak.
- 4) Weak Indian Rupee is a concern after the rupee hit a record low of Rs 85.10 against the dollar, making Indian markets less attractive to foreign investors and raising inflation fears.
- 5) China plans to increase its budget deficit to 4% in 2025, which could restrict foreign inflows into India.
- 6) The street is also apprehensive on the theme that Trump will impose tariffs next year.
- 7) Wall Street key indices too slumped around 4% as investors were seen fleeing after the Federal Reserve rolled back its expectations for 2025 rate cuts.

Long story short: The pessimism was such that there was absolutely no place to run, no place to hide and it looked as if the sky was falling.

Weekly Recap:

Instruments	LTP	Weekly % Change
Nifty	23588	(-4.77%)
Sensex	78042	(-4.98%)
Bank Nifty	50759	(-5.27%)
Nifty Midcap	16456	(-3.50%)
India VIX	15.07	+15.48%
Dow Jones	42199	(-3.66%)
Nasdaq	20950	(-3.84%)
Bovespa	121194	(-2.70%)
Crude Oil	68.62	-3.57%
Gold	2614	-1.18%
Silver	29.28	-3.77%
USD/INR	84.95	+0.16%

Here are how indices performed in the week gone by:

- 1) Nifty sinks as investors looked for massive profit booking, as the benchmark ended the week on a negative note, down 4.77%.
- 2) Bank Nifty too witnessed tough week, plunging 5.27% to end at 50579 level.
- 3) Nifty Private Bank index was seen tumbling, down 5.14% while Nifty PSU Bank index ended 6.3% lower on weekly basis.
- 4) In broader markets, the Nifty Mid-cap 100 index slipped 3.50% while the Nifty Small-cap index dropped 3.57% lower.

Bullish Sectors:

Nifty Pharma (+1.55%)

Bearish Sectors:

Nifty PSE Index (-6.79%)

Nifty Metal (-6.63%)

Nifty Energy (-6.14%)

Nifty Infra Index (-5.58%)

Nifty Auto Index (-5.02%)

Nifty Oil & Gas Index (-4.95%)

Nifty IT (-4.84%)

Nifty Media (-3.35%)

Nifty Reality Index (-2.30%)

Nifty FMCG Index (-2.23%)

STOCK SPECIFIC NEWS:

- 1) IOL Chemicals & Pharmaceuticals ended 1.4% higher at Rs 421 on reports that the company's board will meet on 27 December 2024 to consider and approve sub division or split of existing equity shares of the company.
- 2) SpiceJet was in limelight after the company informed bourses that it has reached a settlement with Genesis to resolve over a \$16 million dispute.
Ajay Singh, Chairman and Managing Director, SpiceJet, said, "This settlement marks another crucial step in our journey towards financial stability."
- 3) ITC has set January 1, 2025 as the appointed date and the effective date for the demerger of the hotel business of the company.
- 4) Vishal Mega Mart, Sail Life Sciences and One Mobikwik Systems have witnessed bumper market debuts. Interestingly, Vishal Mega Mart has crossed the Rs 50,000 crore market capitalisation, while Sai Life Sciences m-cap stands at Rs 15,917 crore, and Mobikwik's current m-cap is Rs 4,120 crore. (At intraweek peak, Mobikwik shares had ringed 89% gains; Vishal Mega Mart, Sai Life had rallied around 40%).
- 5) Aurobindo Pharma Ltd gained 2.76% after announcing that its wholly-owned subsidiary, CuraTeQ Biologics Private Ltd, has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for Zefylti (BP13), a filgrastim biosimilar.
- 6) Wockhardt's stock price is in limelight and at its 52-Week-High After Company's Antibiotic 'Zaynich' Successfully Treated 73 Year Old Cancer Patient.

In the week gone by, notable gainers amongst Nifty 50 were:

DR REDDYYS LAB +7.81%

CIPLA +1.71%

And the losers were:

SHRIRAM FINANCE (-9.02%)

TATA MOTORS (-8.38%)

JSW STEEL (-8.25%)

BHARAT ELECTRONIC (-7.86%)

GRASIM (-7.58%)

The Week Ahead: Amidst a truncated, holiday week, we expect markets to remain sluggish.

Its Christmas week across the globe, where most of the markets will trade only for a few days.

Now speaking about Dalal Street, on the backdrop of massive drubbing, we suspect, pessimism shall still be the preferred theme.

Sentiments continue to remain extremely fragile considering the headwinds and pessimism that are lurking all over Dalal Street.

FII's action will be closely monitored as well because so far in December, they have net sold shares worth Rs. 4,121 crores. Markets require a lot of support from the FII's camp to bounce back. Till then it seems, dark clouds likely to linger on.

Also, one eye will be on geopolitical tensions where Ukraine attacked a town in Russia's Kursk region Friday, killing six people, including a child. As a result, Russia launched an attack in retaliation for Kyiv's firing U.S.-made weapons into Russia. Russia's attacks on Kyiv came one day after Russian President Vladimir Putin's year-end press conference.

Technically speaking, Nifty broke its 4-week winning streak. Not only that, Nifty recorded its worst trading week in last 2 years as well. Also, Nifty has ended well below its 200-DMA at 23834 mark. Confirmation of major strength above 24350 mark. Till then, bears may have an upper hand with downside risks seen till psychological 23000 mark.

The Nifty options data suggests Nifty is likely to be in a trading range of 23200-24200 zone. Maximum Call OI is at 25000 followed by 24000 strike prices. 24000 mark is now Nifty's major resistance zone on closing basis. Maximum Put open interest stands at 23000 levels followed by 23500 levels. Call writing was seen at 23800 and then at 23900 strike price, while there was meaningful Put writing at 23200 and then at 23300 strike prices.

However, the IPO market is likely to remain active as some IPOs are already open for subscription. One of them is Carraro India Ltd which opened for subscription on December 20, 2024 and will close on December 24, 2024. The allotment for the Carraro India IPO is expected to be finalized on Thursday, December 26, 2024. Carraro India IPO will list on BSE, NSE with tentative listing date fixed as Monday, December 30, 2024. Issue size is Rs. 1250 crores. The other is Ventive Hospitality IPO which opened for subscription on December 20, 2024 and will close on December 24, 2024. The allotment for the Ventive Hospitality IPO is expected to be finalized on Thursday, December 26, 2024. Ventive Hospitality IPO will list on BSE, NSE with tentative listing date fixed as Monday, December 30, 2024. Issue size is Rs. 1600 crores.

Bottom-line: The chances of a Santa Rally appear grim.

Price Forecast:

Nifty CMP	(23588)
Support:	23001/22750
RESISTANCE:	23850/24251
RANGE:	23215-23775
200 DMA:	23834
Nifty PCR:	0.70
BIAS:	Negative
Bank Nifty CMP	(50759)
Support:	50000/48700
RESISTANCE:	52000/52900
RANGE:	49800-51777
200 DMA:	50505
BIAS:	Negative

Preferred trade for the week:

Nifty (23588): Sell between 24658-24677 zone. Targets at 23175/23001. Aggressive targets at 22801 zone. Stop at 23921.

TOP SECTORS:

Bullish Sector: PHARMA

Bearish Sectors: AUTO, BANKS, ENERGY, INFRA

STOCKS IN FOCUS:

BULLISH VIEW: DRREDDYS, LUPIN, DIVISLABS

BEARISH VIEW: SBIN, DLF, INFY, CHOLAFIN, BAJFINANCE, UPL, PEL, GRASIM, MPHASIS, COFORGE, LTIM, BAJAJ AUTO, NAUKRI, TATAELXSI, TIINDIA, CAMS, PAGEIND, TATACHEM, L&T, INDIGO

AUROPHARMA

Aurobindo Pharma Ltd. was incorporated in the year 1986 and now commands a market cap of Rs. 72,756 Crores. Founded by Mr. P. V. Ramprasad Reddy and Mr. K. Nityananda Reddy, the firm develops, manufactures, and commercialises a diverse portfolio of generics, specialty products and injectables, active pharmaceutical ingredients and complex offerings including biosimilars, vaccines, peptides, and metered dose inhalers globally in over 150 countries.

The positive catalysts:

- India's second largest pharmaceutical company in terms of revenue, is an integrated global pharmaceutical company headquartered in Hyderabad, India.

- The firm has 29 manufacturing and packaging facilities that are approved by leading regulatory agencies including the US FDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA.
- The robust product portfolio is spread over 7 major therapeutic and product areas encompassing CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.
- Aurobindo Pharma Limited consolidated financial results for the quarter ended September 30, 2024:
 - # Net Profit for the period stood at Rs. 817 crore, vs. Rs. 752 crore in Q2FY24.
 - # Revenue from Operations increased by 8% YoY to Rs 7,796 crore with growth across the businesses.
 - # EBITDA stood at Rs. 1,566 crores with a margin of 20.1% after absorbing higher the R&D costs. EBITDA before R&D was 25.1% and stood at Rs. 1,954 crores versus Rs. 1,936 crores in Q1 FY25.
 - # US formulations (excluding Puerto Rico) revenue increased by 4.3% to Rs. 3,530 crore.
 - # Europe formulations revenue increased by 19% to YoY to Rs. 2,105 crore.
 - # Growth markets revenue increased by 44 YoY to Rs. 812 crore.
 - # 37000+ employees
 - # Out of the total of 227 speciality and injectable ANDA filings as on 30th September 2024, of which 170 have final approval and remaining 57 are awaiting final approval. During the quarter, Aurobindo has filed 10 ANDAs, received final approval of 8 ANDAs and launched 14 products. The company as on 30th September, has 848 ANDAs filed with USFDA on a cumulative basis, out of which 676 have final approval and 26 have tentative approval, and 146 ANDAs are under review.

Outlook: The firm remains confident in maintaining growth momentum, supported by increased volumes, new product launches and stable pricing dynamics. The current pricing environment in the US market is likely to persist, providing a stable foundation for the performance. Europe and growth markets are anticipated to continue their positive growth. The firm is ramping up the capacities in Penicillin G, 6-APA, Granulation and China, which will drive further operational efficiencies and support our growth objectives in the coming quarter. The firm should be able to achieve break-even in the Penicillin G product facility by Q4 FY25 and start contributing positively from FY26 onwards.

Technically, brace yourselves for a major rebound play from a probable classic 'flag pattern' breakout on the yearly charts. An impulse uptrend is seen forming on the daily time scale, with positive SAR series, with recent sequence of higher high/low intact on the weekly and monthly charts.

Add to that a bullish divergence and a rising stochastic signal (on weekly charts) with recent increase in volumes signaling a larger rebound. The 200 days Exponential Moving Average (EMA) of the stock on the daily chart is currently at 1297-1305 zone. The level of Rs 1300 zone will act as a strong resistance zone.

Simply buy at CMP, and on dips between 1100-1150 zone, targeting 1351/1477 mark and then at psychological 1600 mark. Holding Period: 12 Months+

NIFTY AUTO Index vs NIFTY



- **NIFTY AUTO Index: 22,580: UNDERPERFORM.**
- **In Last Week's Trade:** Nifty Auto index witnessed massive drubbing and most importantly, ended the week on a negative note.
- **Relative Strength vs Nifty:** The Nifty Auto index was seen underperforming, ending the week, down 5.02% as against Nifty's 4.77% loss.
- **Nifty Auto index 200 DMA:** 24095 mark.
- **Support:** 22061/20421/18297.
- **Resistance:** 23600/24251/25772. Negative bias as long as 25772 is a resistance. Biggest support at 20421 mark.
- **Preferred Strategy on Auto Index:** Establish sell positions between 23000-23300 zone, targeting 22061/21553 mark and then aggressive targets at 220421-20500 zone with strict stop at 24301.
- **Preferred Trades:**
 - Sell TVS MOTORS (CMP 2392) between 2420-2435 zone, targeting 2363/2281 zone and then aggressive targets at 2175-2200 zone with stop at 2519. Holding Period: 1-2 months.
 - Buy M&M (CMP 2906) between 2800-2825 zone, targeting 3121/3177 zone and then aggressive targets at 3223-3252 zone with stop at 2379. Holding Period: 9-12 months.
- **Outperforming Stocks:** M&M, ASHOK LEYLAND, EICHER MOTORS
- **Underperforming Stocks:** HEROMOTO CORP, BOSCH

PAIR Strategy: Long EICHER MOTORS and Short HEROMOTO CORP.

BANK NIFTY Index vs NIFTY



- **BANK NIFTY Index: 50,759: NEUTRAL.**
- **In Last Week's Trade:** Bank Nifty index witnessed massive drubbing and the negative takeaway was that Bank Nifty snapped its 4 straight week winning streak.
- **Relative Strength vs Nifty:** Bank Nifty mostly mirrored Nifty's sell-off action as the Bank Nifty index ended the week, down 5.27% as against Nifty's 4.77% loss.
- **Bank Nifty 200 DMA:** 50,505 mark.
- **Support:** 49787/4875/46000.
- **Resistance:** 52223/53888/54467.
- **Preferred Strategy on Bank Nifty:** Establish sell positions between 51700-52200 zone, targeting 50201/49787 mark and then aggressive targets at 46000-47000 zone with strict stop at 53901.
- **Preferred Trades:**
 - Buy BANK OF BARODA (CMP 248), between 220-235 zone, targeting 275/289 zone and then aggressive targets at 309-319 zone with stop at 201. Holding Period: 9-12 months.
 - Sell KOTAK BANK at CMP 1744, targeting 1701/1679 zone and then aggressive targets at 1550-1600 zone with stop at 1821. Holding Period: 1-2 months.
- **Outperforming Stocks:** HDFC BANK, ICICI BANK, BANK OF BARODA.
- **Underperforming Stocks:** IDFC FIRST BANK, BANDHAN BANK, KOTAK BANK

PAIR Strategy: Long ICICI BANK and Short BANDHAN BANK.

NIFTY IT Index vs NIFTY



- **NIFTY IT Index: 43,771: NEUTRAL.**
- **In Last Week's Trade:** Nifty IT index witnessed massive corrective decline and the negative takeaway was that Nifty IT index was one of the biggest underperformers.
- **Relative Strength vs Nifty:** Nifty IT index was seen mirroring Nifty's sell-off action. Nifty IT index ended the week, 4.84% lower as against Nifty's 4.77% loss.
- **Nifty IT index 200 DMA:** 38874 mark. Biggest support seen at 43711 mark.
- **Support:** 43111/42201/40000.
- **Resistance:** 45657/46301/47900.
- **Preferred Strategy on Nifty IT Index:** Establish buy positions between 42300-42500 zone, targeting 45657/46301 mark and then aggressive targets at 47001-47900 zone with strict stop at 41769.
- **Preferred Trades:**
 - Buy HCL TECH at CMP 1911, targeting 2001/2029 zone and then aggressive targets at 2150-2200 zone with stop at 1741. Holding Period: 9-12 months.
 - Buy TCS at CMP 4170, targeting 4375/4551 zone and then aggressive targets at 4700-4750 zone with stop at 3841. Holding Period: 5-8 months.
- **Outperforming Stocks:** HCL TECH, MPHASIS, PERSISTENT, TCS, TECH MAHINDRA, INFY, OFSS.
- **Underperforming Stocks:** BSOFT, LTTS

PAIR Strategy: Long HCL TECH and Short BSOFT

NIFTY PHARMA Index vs NIFTY



- **NIFTY PHARMA Index: 22,501: OUTPERFORM.**
- **In Last Week's Trade:** Nifty Pharma index was consolidating with positive bias.
- **Relative Strength vs Nifty:** Nifty Pharma index was seen outperforming Nifty's bearish action. Nifty Pharma index ended the week, up 1.55% as against Nifty's 4.77% loss.
- **Nifty Pharma index 200 DMA:** 21005 mark. Positive bias as long as 21493-mark support is held.
- **Support:** 21900/21350/20200.
- **Resistance:** 22613/23000/23887.
- **Preferred Strategy on Nifty Pharma Index:** Establish buy positions at CMP, targeting 22613/23000 mark and then aggressive targets at 23750-24000 zone with strict stop at 20811.
- **Preferred Trades:**
 - Buy LUPIN at CMP 2151, targeting 2171/2200 zone and then aggressive targets at 2312-2350 zone with stop at 1879. Holding Period: 5-8 months.
 - Buy SUN PHARMA at CMP 1809, targeting 1869/1921 zone and then aggressive targets at 1960-2000 zone with stop at 1683. Holding Period: 5-8 months.
- **Outperforming Stocks:** LUPIN, SUN PHARMA, TORRENT PHARMA
- **Underperforming Stocks:** GRANNULES

PAIR Strategy: Long SUN PHARMA and Short GRANNULES.

NIFTY METAL Index vs NIFTY



- **NIFTY METAL Index: 8,813: UNDERPERFORM.**
- **In Last Week's Trade:** Nifty Metal index was seen falling hard with negative bias as massive profit booking theme prevailed.
- **Relative Strength vs Nifty:** Nifty Metal index was seen underperforming Nifty's sell-off action. Nifty Metal index ended the week, up 6.63% lower as against Nifty's 4.77% loss.
- **Nifty Metal index 200 DMA:** 9269 mark.
- **Support:** 8657/8100/7551.
- **Resistance:** 9291/9750/103221.
- **Preferred Strategy on Nifty Metal Index:** Establish sell positions between 9100-9150 zone, targeting 8657/8500 mark and then aggressive targets at 8100-8250 zone with strict stop at 9791.
- **Preferred Trades:**
 - Sell ADANI ENTERPRISES at CMP 2344, targeting 2250/2100 zone and then aggressive targets at 2025-2050 zone with stop at 2569. Holding Period: 1-2 months.
 - Sell TATA STEEL at CMP 141, targeting 135/129 zone and then aggressive targets at 117-121 zone with stop at 157. Holding Period: 1-2 months.
- **Outperforming Stocks:** RATNAMANI METALS
- **Underperforming Stocks:** SAIL, NMDC, ADANI ENTERPRISES.

PAIR Strategy: Long RATNAMANI METALS and Short SAIL

Stock	CMP	Support	Resistance	21 DMA	200 DMA	Intraday	Short Term	Long Term
ALUMINIUM 1	245	237	252	247	231	DOWN	DOWN	DOWN
COPPER 1	799	783	815	818	823	DOWN	DOWN	UP
CRUDEOIL 1	5944	5825	6063	5850	6387	DOWN	UP	UP
GOLD 1	76432	74903	77961	76388	72464	DOWN	DOWN	UP
LEAD 1	181	176	187	180	186	DOWN	UP	DOWN
NATURALGAS 1	322	312	332	270	201	UP	UP	UP
NICKEL	1336	1309	1363	1634	1950	DOWN	DOWN	DOWN
SILVER 1	88443	86674	90212	90629	86399	DOWN	DOWN	UP
STEEL 1	563	552	574	42125	44492	DOWN	DOWN	DOWN
ZINC 1	279	271	288	285	263	DOWN	DOWN	UP
		0	0					
CASTOR 1	6384	6256	6512	6460	6115	DOWN	DOWN	DOWN
DHANIYA 1	7860	7703	8017	7729	7383	UP	UP	UP
GUARGUM5 1	10376	10168	10584	10147	10529	UP	UP	DOWN
GUARSEED10 1	5260	5155	5365	5143	5347	UP	UP	DOWN
JEERAUNJHA 1	25020	24520	25520	24693	26074	DOWN	UP	DOWN
MENTHAOIL 1	929	910	947	920	931	UP	UP	DOWN
-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-



Share India Securities Limited

Corporate Office

Share India Securities Limited
A-15, Sector-64, Noida-201301
Contact No. : 1800 203 0303

Call Us: 1800 203 0303

Email: support@shareindia.com

Registered Office

Unit No. 615 and 616, 6th Floor, X-Change Plaza,
Dalal Street Commercial Co-operative Society Limited,
Road 5 E, Block 53, Zone 5, Gift City, Gandhi Nagar,
Gujarat-382 355



Disclosures and Disclaimers:

This report has been prepared by Share India Securities Limited (here in after referred to as SISL) in the capacity of a Research Analyst registered with SEBI and distributed as per SEBI (Research Analysts) Regulations 2014. This report is prepared and distributed by Research Analysts employed by SISL for information purposes only, and neither the information contained herein, nor any opinion expressed should be construed or deemed to be construed as solicitation or as offering advice for the purposes of the purchase or sale of any security, investment, or derivatives. The information and opinions contained in the report were considered by SISL to be valid when published. The report also contains information provided to SISL by third parties. Whilst SISL has taken all reasonable steps to ensure that all the information in the report is correct, SISL does not offer any warranty as to the accuracy or completeness of such information. Any person placing reliance on the report does so entirely at his or her own risk and SISL does not accept any liability as a result. Securities markets may be subject to rapid and unexpected price movements and past performance is not necessarily an indication of future performance. Investors must undertake independent analysis with their own legal, tax, and financial advisors and reach their own conclusions regarding investment in securities market and should understand that. Under no circumstances can it be used or considered as an offer to sell or as a solicitation of any offer to buy or sell the securities mentioned within it. The information contained in the research reports may have been taken from trade and statistical services and other sources, which SISL believe is reliable. SISL or any of its group/associate/affiliate companies do not guarantee that such information is accurate or complete and it should not be relied upon as such. Any information provided in the report reflect analysis at this date and are subject to change without notice. SISL submits that no material disciplinary action has been taken on SISL by any regulatory authority impacting Research Analysis activities.

SISL is a Member of National Stock Exchange of India Limited (NSE), BSE Ltd (Bombay Stock Exchange), Multi Commodity Exchange of India Limited (MCX), National Commodity and Derivatives Exchange Limited (NCDEX), and has Depository Participant affiliation with Central Depositories Services (India) Limited (CDSL). It is a SEBI registered Portfolio Manager and SEBI registered Research Analyst [SEBI Reg. No.: INB/F/E 231079832, INB/F/E 011079838, IN-DP-32-2015, AMFI Reg. No. ARN: 78041, SEBI Research Analyst Reg. No.: INH100005011, CIN -L67120GJ1994PLC115132].

Certifications: The Research Analyst(s), Girish Kumar, who prepared this research report hereby certifies

that the views expressed in this research report accurately reflect the research analyst's personal views about all of the subject issuers and/or securities, that the analyst(s) have no known conflict of interest and no part of the research analyst's compensation was, is, or will be, directly or indirectly, related to the Specific views or recommendations contained in this research report.

Additional Disclosures of Interest:

1. The Research Analyst, SISL, or its associates or relatives of the research analyst does not have any Financial interest in the company(ies) covered in this report.
2. The Research Analyst, SISL or its associates or relatives of the research analyst affiliates do not Hold more than 1% of the securities of the company (ies) covered in this report as of the end of the month immediately preceding the distribution of the research report.

3. The Research Analyst, his/her associate, his/her relative, and SISL, do not have any other material conflict of interest at the time of publication of this research report.
4. The Research Analyst, SISL, and its associates have not received compensation for brokerage Services, investment banking, merchant banking or for any other products or services from the Company(ies) covered in this report, in the past twelve months.
5. The Research Analyst, SISL or as associates have not managed or co-managed, in the previous twelve months, a private or public offering of securities for the company (ies) covered in this report.
6. The Research Analyst, SISL or its associates have not received compensation or other benefits from the company(ies) covered in this report or from any third party, in connection with the research report.
7. The Research Analyst has not served as an Officer, Director, or employee of the company (ies) covered in the Research report.
8. The Research Analyst and SISL has not been engaged in market making activity for the company(ies) covered in the Research report.

Suitability and Risks. This research report is for informational purposes only and is not tailored to the specific investment objectives, financial situation or particular requirements of any individual Recipient hereof. Certain securities may give rise to substantial risks and may not be suitable for certain investors. Each investor must make its own determination as to the appropriateness of any Securities referred to in this research report based upon the legal, tax and accounting considerations Applicable to such investor and its own investment objectives or strategy, its financial situation and its Investing experience. The value of any security may be positively or adversely affected by changes in Foreign exchange or interest rates, as well as by other financial, economic, or political factors.

Sources, Completeness and Accuracy: The material herein is based upon information obtained from sources that SISL and the research analyst believe to be reliable, but neither SISL nor the research analyst represents or guarantees that the information contained herein is accurate or complete and it should not be relied upon as such. Opinions expressed herein are current opinions as of the date appearing on this material and are subject to change without notice. Furthermore, SISL is under no obligation to update or keep the information current. Without limiting any of the foregoing, in no event shall SISL, any of its affiliates/employees or any third party involved in or related to computing or compiling the information have any liability for any damages of any kind including but not limited to any direct or consequential loss or damage, however arising, from the use of this report.

Copyright: The copyright in this research report belongs exclusively to SISL. All rights are reserved. Any unauthorised use or disclosure is prohibited. No reprinting or reproduction, in whole or in part, is permitted without the SISL's prior consent, except that a recipient may reprint it for internal circulation only and only if it is reprinted in its entirety.

Caution: Risk of loss in trading/investment can be substantial and even more than the amount / margin given by you. Investment in securities market are subject to market risks, you are requested to read all the related documents carefully before investing. You should carefully consider whether trading investment is appropriate for you in light of your experience, objectives, financial resources and other relevant circumstances. SISL and any of its employees, directors, associates, group entities, or affiliates shall not be liable for losses, if any, incurred by you. You are further cautioned that trading/investments in financial markets are subject to market risks and are advised to seek independent third-party trading/investment advice outside SISL/group/associates/affiliates/directors/employees before and during your trading/investment. There is no guarantee/assurance as to returns or profits or capital protection or appreciation. SISL and any of its employees, directors, associates, and/ or employees, directors, associates of SISL's group entities or affiliates is not inducing you for trading investing in the financial market(s). Trading/Investment decision is your sole responsibility. You must also read the Risk Disclosure Document and Do's and Don'ts before investing.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SISL and affiliates to any registration or licensing requirement within such jurisdiction. The Profits or capital protection or appreciation. SISL and any of its employees, directors, associates, and/or employees, directors, associates of SISL's group entities or affiliates is not inducing you for Trading/investing in the financial market(s). Trading/Investment decision is your sole responsibility.

You must also read the Risk Disclosure Document and Do's and Don'ts before investing.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SISL and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves off and to observe such restriction. For Detailed Disclaimer, please visit our website www.shareindia.com.